RAYOS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RAYOS (RAYOS).
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
| Metabolism | Hepatic via CYP3A4; prednisolone is the active metabolite; undergoes glucuronidation and sulfation; excreted in urine. |
| Excretion | Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount. |
| Half-life | 2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing. |
| Protein binding | 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd ~0.5 L/kg; reflects moderate tissue distribution. |
| Bioavailability | Oral: ~80% (immediate-release); overall ~100% relative to prednisolone; decreased by food. |
| Onset of Action | Oral (immediate-release component): ~1 hour; oral (delayed-release component): variable but designed for morning cortisol peak. |
| Duration of Action | 24 hours (due to delayed-release and immediate-release combination providing sustained effect); clinical duration depends on dose and disease. |
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | No specific dose adjustment required for renal impairment. Monitor for fluid retention and electrolyte disturbances. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: reduce dose by 50% and titrate cautiously. |
| Pediatric use | Weight-based: 0.14-2 mg/kg/day orally divided every 12-24 hours, not to exceed 60 mg/day. Titrate to lowest effective dose. |
| Geriatric use | Initiate at low end of dosing range (e.g., 5 mg/day) due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. Monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RAYOS (RAYOS).
| Breastfeeding | Prednisolone enters breast milk (M/P ratio ~0.15). At maternal doses <20 mg/day, infant exposure <10% of maternal dose; considered compatible. High doses (>40 mg/day) may cause adrenal suppression in infant; avoid breastfeeding for 4 hours after dose. |
| Teratogenic Risk | Pregnancy Category C: Corticosteroids cross placenta. First trimester: Increased risk of cleft palate (odds ratio 3.4). Second/third trimester: Fetal adrenal suppression, intrauterine growth restriction, preterm delivery. Risk proportional to dose and duration. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Systemic fungal infections (except as specific directed therapy)","Hypersensitivity to prednisone or any component of the formulation","Administration of live or attenuated vaccines during immunosuppressive doses","Relative: active peptic ulcer disease, uncontrolled hypertension, diabetes mellitus, osteoporosis, glaucoma"]
| Precautions | ["Increased risk of infections due to immunosuppression; avoid live vaccines.","Hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use; taper dose gradually.","May exacerbate systemic fungal infections; use caution in patients with latent tuberculosis or viral infections.","Monitor for corticosteroid-induced hyperglycemia, hypertension, osteoporosis, and cataract formation.","May mask signs of infection or worsen existing infections."] |
Loading safety data…
| Fetal Monitoring |
| Maternal: Blood pressure, blood glucose, signs of infection, adrenal suppression. Fetal: Serial growth ultrasound (every 4 weeks) for growth restriction; fetal heart rate monitoring if preeclampsia or preterm labor signs. |
| Fertility Effects | Corticosteroids may suppress HPA axis and inhibit ovulation; reversible upon dose reduction or discontinuation. Sometimes used as adjunct in infertility conditions (e.g., autoimmune), but no direct toxicity to gametes. |